- Home
- MDGL vs OWL Comparison
MDGL vs OWL Comparison
Compare MDGL & OWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDGL | OWL |
|---|---|---|
| Founded | 2011 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 9.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MDGL | OWL |
|---|---|---|
| Price | $582.30 | $15.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 15 |
| Target Price | ★ $543.33 | $22.50 |
| AVG Volume (30 Days) | 415.7K | ★ 15.5M |
| Earning Date | 11-04-2025 | 10-30-2025 |
| Dividend Yield | N/A | ★ 6.01% |
| EPS Growth | N/A | ★ 47.85 |
| EPS | N/A | ★ 0.08 |
| Revenue | $740,640,000.00 | ★ $2,745,943,000.00 |
| Revenue This Year | $395.75 | $17.06 |
| Revenue Next Year | $65.73 | $21.21 |
| P/E Ratio | ★ N/A | $193.26 |
| Revenue Growth | ★ 864.21 | 27.24 |
| 52 Week Low | $265.00 | $13.25 |
| 52 Week High | $605.00 | $26.73 |
Technical Indicators
Market Signals| Indicator | MDGL | OWL |
|---|---|---|
| Relative Strength Index (RSI) | 66.51 | 57.92 |
| Support Level | $569.04 | $14.73 |
| Resistance Level | $598.77 | $15.19 |
| Average True Range (ATR) | 26.64 | 0.58 |
| MACD | 0.06 | 0.22 |
| Stochastic Oscillator | 75.05 | 99.80 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About OWL Blue Owl Capital Inc.
Blue Owl Capital is one of the world's largest alternative-asset managers, $295.6 billion in total managed assets, including $183.8 billion in fee-earning AUM, at the end of September 2025. The company has three core business segments: global private equity, (with $68.8 billion in total AUM and $40.2 billion in fee-earning AUM), private credit ($152.1 billion/$97.3 billion), and real estate/real assets ($74.7 billion/$46.3 billion). The firm primarily serves institutional investors (68% of AUM) and high-net-worth individuals (32%). The firm operates through more than 20 offices in the Americas, and the EMEA and Asia-Pacific regions.